Abstract
Background Chronic liver disease (CLD) is a progressive condition that, in its advanced stages, leads to cirrhosis with related clinical complications, and can lead to acute-on-chronic liver failure (ACLF) - a syndrome marked by critical illness, multi-organ dysfunction and high mortality. Systemic inflammation in ACLF can occur without overt infection, indicating alternative pathways of immune activation and microbial translocation. Intestinal perturbations, bacterial translocation, and the resulting systemic inflammation and immune dysfunction are defining features of ACLF, yet the identification of specific microbial contributors remains poorly elucidated.
Objective To investigate the relationship between gut microbiome alterations, systemic inflammation, and clinical markers of disease severity across the cirrhosis spectrum.
Design This cross-sectional, prospective study analysed faecal microbiota, plasma bile acids, urinary and plasma metabolites, markers of gut and systemic inflammation and translocation, and monocyte dysfunction, in a well-phenotyped cohort of patients with ACLF, decompensated cirrhosis and stable cirrhosis, in comparison with healthy individuals.
Results Advanced stages of cirrhosis were marked by a higher abundance of Enterococcus, which correlated with markers of systemic inflammation, particularly in ACLF patients. Concurrently, the abundance of anaerobic commensal genera such as Roseburia, Ruminococcus, and Faecalibacterium were significantly lower. Lower urinary hippurate and trimethylamine N-oxide TMAO levels, linked to reduced microbial metabolism and dietary fibre intake, paralleled these microbiome changes. While elevated plasma primary bile acids reflected hepatic dysfunction, systemic inflammatory markers suggested parallel gut barrier dysfunction and microbial translocation in advanced cirrhosis.
Conclusion This study underscores a potential role of greater intestinal Enterococcus abundance, as cirrhosis severity increases and where clinically there is more antibiotic exposure, as a driver of gut barrier inflammation and dysfunction, and systemic immune dysfunction in advanced cirrhosis. Further research into tailored microbiome-targeted therapies, including prebiotics and probiotics, and more focused antibiotic use may prevent Enterococcus dominance and restore gut-liver axis homeostasis and mitigate disease progression in CLD.
What is already known on this topic
CLD can progress to ACLF, a life-threatening syndrome with high mortality rates characterised by systemic inflammation, impaired phagocytosis and immune dysfunction with associated multiple organ failure.
The gut microbiome’s role in underpinning the gut-liver axis is recognised, with microbial perturbations and gut barrier dysfunction associated with CLD, yet the exact microbiome changes and their link to inflammatory pathways remain unclear.
What this study adds:
This study reveals that Enterococcus significantly increases with CLD severity and antibiotic use and correlates with markers of systemic inflammation and gut barrier dysfunction.
Reductions in obligate anaerobe commensal bacteria, such as Roseburia and Faecalibacterium, are observed, alongside depressed levels of key microbial metabolites, including hippurate and TMAO, across CLD stages.
These changes suggest that Enterococcus predominance and gut microbiome perturbations driven by factors including disease severity and antibiotic use may actively drive inflammation and impaired monocyte function in CLD.
How this study might affect research, practice, or policy
Findings indicate that Enterococcus and wider gut microbiome perturbations provide a rationale for targeting as therapeutic strategies to modulate the gut-liver axis in CLD.
This highlights the potential of microbiome-focused interventions, such as faecal microbial transplantation, probiotics, prebiotics or phages, to improve gut health, reduce gut and systemic inflammation, and ultimately mitigate cirrhosis-related complications.
Future research and development of targeted microbiome therapeutics may positively influence CLD management including a focus on antimicrobial stewardship, and inform clinical guidelines whilst improving patient outcomes.
Competing Interest Statement
VCP has undertaken consultancy for Norgine Pharmaceuticals Ltd, Alfasigma S.p.A. and Menarini Diagnostics Ltd. DLS has undertaken consultancy for Norgine Pharmaceuticals Ltd, EnteroBiotix, MRM Health, Apollo Therapeutics, Genfit and Satellite Biosciences. RPV reports Honoraria from Novo Nordisk, Amarin UK and AstraZeneca. AS has delivered paid lectures for Bristol Myers Squibb. MD, LH, RK, GR, SS, SC, KB, MJWM have no conflicts.
Funding Statement
The observational study was adopted to the National Institute for Health Research (NIHR) Clinical Research Network (CRN) portfolio supporting participant screening and recruitment by the Liver Research and Anaesthetics Critical Care Emergency and Trauma Teams at Kings College Hospital NHS Foundation Trust. VCP was supported by a New Investigator Award from the Intensive Care Foundation (Registered charity number: 2940178) and Clinical Research Network South London Principal Investigator Strategic GreenShoot Research Delivery and Development Funding. The clinical trial was funded through an investigator-initiated study grant awarded by Norgine Pharmaceuticals UK Limited to Kings College London. Infrastructure to support the trial was also provided by the Medical Research Council (MRC) Centre for Transplantation, Kings College London UK MRC grant no. MR/J006742/1. Laboratory assays were also part funded by a generous donation from a Liver Service User to the Kings College Hospital Institute of Liver Studies and Transplantation Charity Research Fund, Kings College Hospital Charity (Registered charity number: 1165593). MS, BA, MEM, MM, SC and VCP were supported and bioinformatic analyses were part funded by the Foundation for Liver Research (Registered charity number: 268211/1134579). LJH is supported by Wellcome Trust Investigator Award (220876/Z/20/Z); the Biotechnology and Biological Sciences Research Council (BBSRC), Institute Strategic Programme Gut Microbes and Health (BB/R012490/1), and its constituent projects BBS/E/F/000PR10353 and BBS/E/F/000PR10356, and the BBSRC Institute Strategic Programme Food, Microbiome and Health BB/X011054/1 and its constituent project BBS/E/QU/230001B. MT Acknowledges support from the NIHR-Imperial Biomedical Research Centre and the Medical Research Council Precision Medicine Award (MR/R014019/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The observational study was granted approval by the NHS Health Research Authority NRES Committee London Westminster [REC reference: 12/LO/1417] and local sponsor Research and Development department (KCH12-126). Ethical approval for the interventional trial was obtained from NHS Health Research Authority NRES Committee South Central-Oxford C (Bristol) [REC reference: 14/SC/0088] and from the Medicines and Healthcare products Regulatory Agency for Clinical Trial Authorisation [EudraCT number: 2013-004708-20; ClinicalTrials.gov NCT02019784]. The studies were conducted in compliance with the principles of the Declaration of Helsinki (1996), principles of Good Clinical Practice, Research Governance Framework and where relevant, the Medicines for Human Use (Clinical Trial) Regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The 16S rRNA amplicon sequencing raw reads are deposited in NCBI SRA under project PRJNA1223169.
